Don L Bowcut, MD in Springville, UT - Family Medicine

Don L Bowcut, MD is a Family Medicine physician based in Springville, Utah. Don L Bowcut is licensed to practice in Utah (license number 1868471205) and his current practice location is 385 S 400 E, Springville, Utah. He can be reached at his office (for appointments etc.) via phone at (801) 489-3244.

NPI number for Don L Bowcut is 1730195967 and his current mailing address is Po Box 27128, Salt Lake City, Utah. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1730195967.

Contact Information

	Don L Bowcut, MD
	385 S 400 E, Springville, UT 84663-1955
	(801) 489-3244
	Not Available

Physician's Profile

Full Name	Don L Bowcut
Gender	Male
Speciality	Family Medicine
Location	385 S 400 E, Springville, Utah
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1730195967
Provider Enumeration Date: 07/31/2006
Last Update Date: 07/21/2008

Medical Identifiers

Medical identifiers for Don L Bowcut such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1730195967	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207Q00000X	Family Medicine	1868471205 (Utah)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Don L Bowcut is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Don L Bowcut, MD Po Box 27128, Salt Lake City, UT 84127-0128 Ph: (801) 489-3244	Don L Bowcut, MD 385 S 400 E, Springville, UT 84663-1955 Ph: (801) 489-3244

News Archive

Hygeia questions the recently issued state bid notification for breastpumps

In the USA, each state is responsible for its Women Infant Children program and encourages breastfeeding through lactation counseling and the purchase of supplies. A state bid notification for breastpumps and supplies was recently issued. "This bid had such an unusual feature that needs further attention. The bid's breastpump requirement was that the pumps only had to work for 90% of the women. The state felt that it was acceptable for the pumps to fail for 10% of the women," stated John Estill, CEO of breastpump manufacturer Hygeia.

Fluidigm releases amplicon tagging protocol for Illumina GA II next-generation sequencer

Fluidigm Corporation today announced the release of its amplicon tagging protocol for the Illumina GA II next-generation sequencer. The 48.48 Access Array integrated fluidic circuit (IFC) allows Illumina GA II users to automatically prepare sequencing-ready libraries from 48 individual samples at a time, for as little as $7 (U.S.) per sample.

Research describes novel molecules designed to treat or prevent COVID-19 infection

Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO).

Family Medicine Doctors in Springville, UT

Dr. Michael S Mclay, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5 E 400 N, Springville, UT 84663 Phone: 801-489-8464 Fax: 801-489-6378
William David Voss, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 376 E 400 S, Springville, UT 84663 Phone: 801-491-9355 Fax: 801-491-3000
Stephen Takasaki, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 5 E 400 N, Springville, UT 84663 Phone: 801-489-8464 Fax: 801-798-8513
Dr. Edward William Jackson, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 786 S Left Hand Fork Hobble Creek Cyn, Springville, UT 84663 Phone: 801-489-9381
Ian Mcmaster, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 672 W. 400 S., Suite 101, Springville, UT 84663 Phone: 801-491-9883 Fax: 801-489-3141
Russell Beckstead, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5 E 400 N, Springville, UT 84663 Phone: 801-489-8464 Fax: 801-798-8513

Don L Bowcut, MD - Family Medicine in Springville, UT